Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

ADC Therapeutics: US$325m for ADC royalties

The Lausanne-based biotechnology company has entered into a US$325m financing agreement with healthcare investment firm HealthCare Royalty Partners....

Boehringer walks away from CureVac deal

CureVac announced the termination of the 2014 programme BI1361849 in its financial report. Seven years ago, CureVac had received €35m upfront, with...

Cardior bags €64m in Series B Financing

The €64m Series B financing was led by l Inkef Capital with new co-investors Fund+, Sunstone, Hadean Ventures and Coparion participating. In...

US$21m for microbiome therapies

Scottish biopharmaceutical company EnteroBiotix is focussed on addressing a wide range of diseases by enhancing the diversity of the microbiome. Now,...

Touchlight extends funding round to boost DNA vector manufacture

The company said it will use the funds to expand production capacity for its enzymatically produced synthetic (“doggybone DNA™”) DNA vector, dbDNA™...

NeuVasQ Biotechnologies bags €20m in Series A financing

Brussels-Basel VC investor Newton Biocapital led the financing round with a €10m contribution from its Newton Biocapital I fund.  Another €10m...

Foundation launches Harvard research hub

The foundation and the Broad Institute have joined up to launch the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative...